Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict heart attacks before they happen

NCT ID NCT05800093

Knowledge-focused Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how combining blood tests (proteomics and genomics) with CT scans can help predict the worsening of coronary artery disease. Researchers will follow 310 adults aged 50-75 who have early signs of plaque in their heart arteries but no symptoms. The goal is to better understand which plaques are dangerous and may lead to future heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

310 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients between 50 and 75 years old with nonobstructive coronary artery disease

Ages

50 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients between 50 and 75 years old * Subjects at intermediate to high risk for ASCVD * Asymptomatic patients without cardiac chest pain * Evidence of atherosclerosis on baseline CCTA Exclusion Criteria: * Renal insufficiency, defined as eGFR \< 30 ml/min * History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke) * Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy * Change in lipid lowering therapy in the last 6 months * Use of more than two antihypertensive agents * No coronary atherosclerosis at baseline imaging * Active malignancy requiring treatment * Atrial fibrillation * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease progression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease progression

Contacts and locations

Locations

  • Amsterdam UMC, location AMC

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.